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ABSTRACT
In bronchial asthma, respiratory virus infection involves several issues: 1) respiratory virus infection in infancy is
a risk factor for, and may predispose to, the development of asthma later in life; 2) respiratory virus infection is
associated with the acute exacerbation of bronchial asthma; and, 3) glucocorticosteroids (GC) are not ade-
quate for controlling asthma-related symptoms upon respiratory virus infection. Various cells, inflammatory me-
diators and cytokines participate in the production of airway inflammation upon respiratory virus infection. Bron-
chial epithelial cells are a site of infection and replication of respiratory virus. They actively participate in the
production of airway inflammation: 1) they produce various proinflammatory cytokines, chemokines and media-
tors; and, 2) they undergo apoptosis, thereby impairing the repair process. It is therefore important to under-
stand the role of bronchial epithelial cells in the pathophysiology of bronchial asthma. In this review, the interac-
tion between viral infection and asthma is discussed to elucidate the role of bronchial epithelial cells in viral in-
fection.
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INTRODUCTION
Rhinovirus, respiratory syncytial virus (RSV), metap-
neumovirus, influenza virus, and parainfluenza virus
infections in bronchial asthma patients have been im-
plicated in several issues.1,2 Firstly, respiratory virus
infection is associated simultaneously with the etiopa-
thogenesis and the acute exacerbation of bronchial
asthma.3,4 Recurrent severe respiratory virus infec-
tions in infancy are acknowledged as a risk factor for,
and may well predispose the patient to, the develop-
ment of asthma later in life. Secondly, bronchial asth-
matics have increased susceptibility to respiratory vi-
rus infections presenting more respiratory symp-
toms, combined with reductions in pulmonary func-
tioning, than normal subjects who are similarly in-
fected.3,5 Thirdly, glucocorticosteroids (GC) are
widely used for the management of bronchial asthma
because of their anti-inflammatory effects; however;
the efficacy of GC on respiratory virus infection-
induced wheezing episodes and on the acute exacer-
bation of bronchial asthma in general, is insuffi-
cient.6,7 Other therapeutic options should therefore
be investigated.
Bronchial epithelial cells are found at the site of
respiratory virus infection and replication. They are
involved in the production of airway inflammation
upon viral infection by their expression of proinflam-
matory cytokines, chemokines and mediators, and
also by the fact that they can be responsible for the
loss of the epithelial barrier function.8-11 In this re-
view, the interaction between viral infection and
asthma is discussed to elucidate the role of bronchial
epithelial cells.
DEVELOPMENT OF ALLERGY AND ASTH-
MA
In infancy, acute episodes of wheezing, which are
predominantly caused by respiratory virus infections,
are an important cause of death.12 Respiratory virus
infection in infancy also implies an increased risk of
the later development of asthma. Immunological re-
sponses at birth may determine and predict a risk of
acute episodes of wheezing.13-15 Interferon-(IFN) γ
production by cord blood lymphocytes stimulated
with RSV or phytohemaggulutinin (PHA) is associ-
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ated both with anti-viral activity and the rate of wheez-
ing in the first year of life.15 There have been several
risk factors associated with the development and per-
sistence of asthma documented, including the follow-
ing: low birth weights; reduced lung functioning; ex-
posure to second hand smoke; a maternal history of
allergy; elevated serum IgE levels; and, the presence
of atopy.16-19 Respiratory virus infection in early life,
particularly in infancy, is an important risk factor for
the development of asthma later in life. There are sev-
eral reasons why respiratory virus infection influ-
ences asthma development. Firstly, infancy is a pe-
riod of time which is characterized by lung develop-
ment, including alveolar multiplication and airway
growth, and it is also a time of heightened susceptibil-
ity to viral infection;13,14,20 therefore, viral infection
could adversely affect lung development.21 Secondly,
epidemiological studies have shown that severe and
or repeated respiratory viral infections in the lower
respiratory tract in infancy influences immune re-
sponses. The interaction between respiratory viral in-
fection and allergen exposure in Th-1 or Th-2 polar-
ized responses has been extensively investigated in
animal models of allergic asthma and child asthmat-
ics.12,13,22-25 It is not clearly understood, but in gen-
eral, timing and severity of viral infection determines
Th-1 or Th-2 polarized responses.12,13,22-25 For in-
stance, when RSV infection and allergen exposure are
concurrent, Th-2 responses are enhanced; however, if
RSV infection precedes allergen exposure, Th-2 re-
sponses are not enhanced.25
ACUTE EXACERBATION
Several factors, including microbes such as respira-
tory viruses, allergens, environmental pollutants, oc-
cupational irritants, medications such as aspirin and
mental stress are known to cause the acute exacerba-
tion of bronchial asthma26-28. In school age children,
about 80% of acute exacerbation is associated with vi-
ral infection. In adults, although the rates of detection
and isolation of viruses varies widely in different stud-
ies, respiratory viral infection is the most common
cause of acute exacerbation.26-28 Bronchial asthmatics
have generally more susceptibility to respiratory vi-
rus infection. They are more likely to develop lower
respiratory symptoms and these symptoms are likely
to persist for long periods of time.
Mechanisms involved in the respiratory virus
infection-triggered acute exacerbation of bronchial
asthma have been extensively investigated. Bronchial
epithelial cells are the site of viral infection and repli-
cation. Cellular responses and damage to epithelial
cells upon viral infection are known to be involved in
and possibly trigger the acute exacerbation of bron-
chial asthma.26-28 A variety of proinflammatory cytoki-
nes, chemokines and proallergic cytokines are up-
regulated during the acute exacerbation of asthma.
Cellular profiles and cytokine patterns in the airways
in virus-triggered acute exacerbation cases differ
from those in allergen-triggered exacerbation ca-
ses.26-28 In virus-triggered acute exacerbation, there
are the following: bronchial mucosa neutrophilia and
eosinophilia; up-regulation of CXCL8 (interleukin-8;
IL-8) and its receptors; up-regulation of CXCL5 (epi-
thelial cell-derived neutrophil attractant 78), and its
receptors; CXCR1; and, CXCR2. CCL5 (RANTES) is
also up-regulated.29-31 By contrast, there is bronchial
mucosa eosinophilia and increased IL-5-positive cells
in allergen-triggered acute exacerbation.27 The
mechanisms might be different between them. For
instance, airway epithelial cells are the primary target
cells for viruses, since respiratory viruses infect and
replicate in airway epithelial cells; however, for aller-
gens, bronchial epithelial cells are not the primary
target cells. It is also important for allergens to pass
through the epithelial cell barrier and reach the inter-
nal milieu of the airway.
TOLL-LIKE RECEPTOR
The toll-like receptor (TLR) plays an important role in
pathogen recognition and in innate immunity. Airway
epithelial cells constitutively express the ten mem-
bers of the TLR family and their ligands which have
been identified.32 Among these 10, the biological
functions of TLR2, TLR3 and TLR4 and their roles in
airway inflammation have been well documented.
TLR3 binds double strand RNA (dsRNA) synthesized
in virus-infected cells. This binding of dsRNA to TLR3
induces the production of various proinflammatory
cytokines, chemokines and interferon (IFN).33
TLR EXPRESSION
TLR3 is constitutively expressed, but up-regulated by
microbe infections including bacteria and viruses.34
Recently it was discovered that H. influenzae infection
potentiates airway epithelial cell responses to rhinovi-
rus by expressing both the intracellular adhesion
molecule-1 (ICAM-1) and TLR3.35 Histamine also up-
regulates TLR3.36 Thus, local inflammation influences
TLR3 expression. In addition, RSV infection sensi-
tized airway epithelial cells to bacterial endotoxins
and lipopolysaccharides (LPS) via the up-regulation
of TLR4 expression.37 TLR4, which is a ligand for
LPS, also recognizes viral motifs including the F pro-
tein of RSV.38 Results from the data on the impaired
host defense against RSV infection in TLR4-deficient
mice have shown that TLR4 plays an important role
in RSV infection.39 Recently, Tulic M et al. have
shown that children, who demonstrate expression of
certain TLR4 genotypes, may have more susceptibil-
ity to RSV infection.40 Since repeated and severe res-
piratory virus infections, including RSV, is suggested
to be a risk factor for developing bronchial asthma, it
is necessary to clarify whether children with certain
TLR4 genotypes would develop bronchial asthma.
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DEFICIENT INNATE IMMUNITY AGAINST VIRUS
INFECTIONS
As for the responsiveness of bronchial epithelial cells
to respiratory virus infections, asthmatics have been
shown to have impaired IFN production of their bron-
chial epithelial cells; moreover, their bronchial epi-
thelial cells demonstrate a decrease in IFN-β expres-
sion and cell apoptosis occurs upon rhinovirus infec-
tion which results in increased virus replication oc-
curring.41 Rhinovirus load in asthmatic bronchial epi-
thelial cells correlated significantly with abnormal
pulmonary function. Thus, increased susceptibility to
rhinovirus infection and virus replication in the bron-
chial epithelial cells in asthmatics may be closely
linked to the development of not only bronchial
asthma symptoms but also to bronchial asthma itself.
Recently, deficient IFN-λ production and increased vi-
rus replication in the bronchial epithelial cells from
asthmatics also has been proven.42 Rhinovirus infects
the cells via ICAM-1 and subsequently enters the
cells. After entry, dsRNA is synthesized in the cells.
ICAM-1-mediated signals and TLR3-mediated signals
are both able to induce IFN production.43 Blocking of
TLR3 results in a decrease in antiviral activity against
rhinovirus infection.44 Differences in TLR3 expres-
sion, on airway epithelial cells and polymorphisms in
genes encoding TLR3, might be a potential mecha-
nism which can account for the impaired interferon
responses to viral infection; however, there have
been no reports to support this hypothesis. Further
studies should be pursued to elucidate the mecha-
nisms involved in impaired IFN expression upon rhi-
novirus infection.
EPITHELIAL CELLS IN AIRWAY INFALAM-
MATION AND REMODELING
The intact epithelial cells, and the tight junctions be-
tween them, form a barrier between the external and
internal milieu of the airway. This physiological bar-
rier prevents invading environmental agents from
transferring from the lumen to the interstitium via the
paracellular route and thusly it prevents them from
contacting subepithelial basement membranes.45 In
addition to their function as a physiological barrier,
they produce airway secretory proteins, which clear
out inhaled agents, and cytokines, which attract and
activate inflammatory cells to facilitate them to work
on the host defense.9-11,46 Thus, bronchial epithelial
cells play a pivotal role in the host defense and in the
normal homeostasis of the internal milieu of the res-
piratory system, while epithelial cells are actively in-
volved in the production of airway inflammation and
remodeling: 1) they produce various cytokines and
mediators; 2) they undergo injury and their repair
process is impaired; and, 3) they lose or become defi-
cient as regards the function of the epithelial tight
junction.9-11,46 Why does airway inflammation and re-
modeling occur in bronchial asthmatics when they in-
spire environmental agents and gases but not in non-
asthmatics? A reasonable answer could be that the
bronchial epithelial cells of asthmatics have several
different characteristic features.
There are several reports describing the different
degrees of susceptibility of bronchial epithelial cells
to various stimuli in asthmatics. The bronchial epithe-
lial cells of asthmatics produce more cytokines in re-
sponse to DEP and have more susceptibility to
oxidant-induced injuries;9-11,46 this indicates that the
characteristic features of bronchial epithelial cells
might be closely related to chronic airway inflamma-
tion. These results were obtained from the bronchial
epithelial cells of adult asthmatics. Airway inflamma-
tion and treatment could modify the characteristic
features of the bronchial epithelial cells and it is im-
portant to determine when these characteristic fea-
tures occur and how inherited factors contribute to
these characteristic features. A recent study has dem-
onstrated that the bronchial epithelial cells from asth-
matic children also have intrinsic biochemical and
functional differences from normal healthy controls.47
The interaction between genetic and environmental
factors may contribute to the pathogenesis of bron-
chial asthma; therefore, genetic factor(s) predispos-
ing susceptibility of bronchial epithelial cells to vari-
ous stimuli should be clarified.
CYTOKINE PRODUCTION AND MEDIATOR RE-
LEASE
Bronchial epithelial cells are the site of viral replica-
tion and actively participate in airway inflammatory
responses by their expression of various cytokines
and mediators. Various inflammatory and immuno-
competent cells, including macrophages, dendritic
cells, lymphocytes, mast cells, eosinophils and neu-
trophils, are involved in the production of allergic air-
way inflammation and remodeling in bronchial
asthma patients. Several factors stimulate bronchial
epithelial cells to produce proinflammatory cytokines,
chemokines and arachidonic acid metabolites: envi-
ronmental factors, including air pollutants; alterations
in airway osmolarity and temperature; and, microbes
including viruses. These cytokines and mediators re-
cruit inflammatory and immunocompetent cells into
the sites of airway inflammation.9-11,46
There are a variety of cytokines and chemokines
which influence cell functions. EotaxinCCL11 and
RANTESCCL5, stem cell factor (SCF) and thymic
stromal lymphopoietin (TSLP), IL-8CXCL8, ENA-
78CXCL5 and neurotropin, TARC, MDC and IP-10,
and B-cell activating factors are all produced by bron-
chial epithelial cells stimulated by proinflammatory
stimuli and microbes, including respiratory virus in-
fection, and they recruit and activate eosinophils,
mast cells, neutrophils, Th2 cells and B cells, respec-
tively.48-55 These cells influence each other and or-
chestrate the cascade like production of airway in-
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flammation. Mast cells and eosinophils are found in
increased numbers in the airways of bronchial
asthma patients and they play an important role in the
production of airway inflammation and remodeling,
although recent data has brought into question the
pivotal role of eosinophils in airway hyperresponsive-
ness and the clinical features of asthma.56 Neutro-
phils are found in increased numbers in the airways
of bronchial asthma patients, particularly in instances
of severe asthma and at the acute exacerbation
phase.57 Thus, epithelial cell-derived cytokines and
chemokines participate in recruiting and activating in-
flammatory and immunocompetent cells. Recruited
cells, in turn, influence epithelial cell functions. For
instance, eosinophil-secreted products, including
eosinophil cationic protein (ECP), major basic protein
(MBP), eosinophilic peroxidase (EPO), and neu-
trophil-secreted products, including neutrophil
elastase, injure epithelial cells and increase epithelial
permeability.58,59 IL-17A, which is mainly produced
by activated T cells synergistically, enhances
rhinovirus-induced IL-8 and human beta-defencin-2
(HBD-2) production by bronchial epithelial cells.60 IL-
8 recruits neutrophils and HBD-2 recruits immature
dendritic cells and memory T cells into the airways.
Dendritic cells play an important role in immunologic
and allergic responses including in antigen recogni-
tion. Thus, the interaction between epithelial cells
and various other cells orchestrates the production of
airway inflammation and could lead to an acceleration
of airway inflammation.
There are two major arachidonic acid metabolic
pathways: the cyclooxygenase (COX) pathway; and,
the 5-lipoxynase (5-LO) pathway. COX-1 and COX-2,
two isoforms of COX, catalyze the synthesis of
prostaglandin (PG) H2 from arachidonic acid. PGH2
is then metabolized to various PGs, such as PGE2,
PGD2, PGI2, and thromboxane A2 (TxA2). COX-1 is
constitutively expressed, but COX-2 is inducibly ex-
pressed. 5-LO generates cysteinyl-LTs (cys-LTs) and
LTB4. Individual PGs have different roles in allergic
inflammation, such as inducing andor regulating the
inflammation. Cys-LT, LTC4, LTD4 and LTE4 cause
bronchoconstriction, mucosal edema, mucus hyper-
secretion and eosinophils chemotaxis. LTB4 induces
neutrophil chemotaxis. In allergic inflammation, pro-
allergic cells, mast cells and eosinophils basically syn-
thesize and release PGs and LTs. Recently, the ex-
pression of COX-2 and 5-LO in bronchial epithelial
cells expression has been shown. Upon respiratory
infection, respiratory virus infection and dsRNA up-
regulation, COX-2 expression occurs and the subse-
quent release of PGs and LTs occurs.61,62 Thus, ara-
chidonic acid metabolites released from bronchial
epithelial cells upon viral infection participate in the
acute exacerbation of bronchial asthma.
THYMIC STROMAL LYMPHOPOIETIC
TSLP was originally identified as supporting the
maturation and differentiation of B cells and the pro-
liferation of T cells. In addition to its known activities,
new roles for TSLP in allergic inflammation have re-
cently been documented. TSLP activates myeloid
dendritic cells to polarize Th2 responses. TSLP which
is a novel IL-7-like cytokine was originally identified
in the supernatants produced from the mouse thymic
stromal cell lines.63 TSLP supports the maturation
and differentiation of B cells and the proliferation of T
cells. In addition to its function on pre-B cell matura-
tion, TSLP is shown to function as a Th2-polarized im-
mune response through the activation of myeloid
dendritic cells. TSLP activates immature myeloid
dendritic cells to up-regulate co-stimulatory mole-
cules such as CD40, OX40 and CD80 in order to ac-
quire the capacity to induce Th2 responses. TSLP can
stimulate the differentiation and activation of imma-
ture dendritic cells to induce the expression of Th2
cell attracting chemokines such as CCL17 and CCL
22. Native CD4+ T cells primed by TSLP-stimulated
dendritic cells produce proallergic cytokines such as
IL-4, IL-5 and IL-13, and tumor necrosis factor (TNF)
-α, but little or no IL-10 or IFN-γ. Thus, TSLP is able
to trigger dendritic cell-mediated Th2 immune re-
sponses.64-66
The role of TSLP in allergic inflammation has been
explored. The critically important role of TSLP in the
triggering and the production of allergic inflamma-
tion in asthmatics is supported by the following data:
1) TSLP mRNA expression is increased in asthmatic
airways and it correlates with Th2-attracting
chemokine expression and with disease severity67―
in mice, TSLP expression in the lungs of mice with
antigen-induced asthma is increased; 2) TSLP
receptor-deficient mice had much lower Th2 re-
sponses and considerably reduced allergic airway in-
flammations in the airways;68 3) lung-specific expres-
sion of TSLP transgene induces allergic inflammation
of the airways with eosinophilia, goblet cell hyperpla-
sia and subepithelial fibrosis;68 4) TSLP is able to trig-
ger dendritic cell-mediated Th2 immune re-
sponses;64-66 and, 5) TSLP induces IL-5, IL-13, IL-6,
GM-CSF, CXCL8 and CCL1 production by mast cells,
although TSLP did not induce mast cell degranula-
tion or lipid mediatory release.64-66
TSLP is expressed in human skin keratinocytes,
bronchial epithelial cells, smooth muscle cells and
lung fibroblasts, but not in most hematopoietic cells,
including B cells, T cells, natural killer cells, macro-
phages, monocytes, dendritic cells, and neutrophils.
Airway epithelial cells express and produce TSLP
mRNA and protein in response to proinflammatory
cytokines, including IL-1 and TNF-α, and proallergic
cytokines, including IL-4 and IL-13;51 furthermore,
TLR ligands, peptidoglycan (PGN), dsRNA, and rhi-
novirus infections are able to induce TSLP production
Viral Infection in Asthma
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by airway epithelial cells.50,51 In addition to TSLP-
triggered dendritic cell-mediated Th2 immune re-
sponses, since TSLP activates mast cells to produce
Th2 type cytokines, epithelial cell-derived TSLP upon
respiratory virus infection may play an important role
in the initiation and promotion of allergic inflamma-
tion independent of the Th2-type T cell and IgE-
dependent mechanism. TSLP also might also be in-
volved in the possible mechanism involved in the
acute exacerbation of asthma upon viral infection.
EPITHELIAL BARRIER FUNCTION AND
PERMEABILITY
There are two major routes for environmental agents
and microbes to reach the internal milieu of the air-
way. Injuring epithelial cells and disrupting epithelial
tight junctions, resulting in increased epithelial per-
meability, allows the environmental agents to invade
the internal milieu.
EPITHELIAL CELL APOPTOSIS, REMOVAL OF
DYING CELLS AND REPAIR
Innate immunity and adaptive immunity co-operate in
the host defense against respiratory virus infections.
Major host defense mechanisms against respiratory
virus infections are as follows: 1) antiviral cytokines
including IFN; 2) cell lysis by cytotoxic T cells and
natural killer T cells; 3) cell apoptosis to abort the vi-
rus propagation process; 4) immunoglobulin; 5) sur-
factant and defensin; and, 6) barrier function of bron-
chial epithelial cells.69-72 The antiviral response by ex-
pressing IFN is important for protecting cells against
viral infections and replication. Cell apoptosis is a
critical process for the pathogenesis of certain dis-
eases. In the case of respiratory virus infections,
apoptosis and phagocytosis, of apoptotic cells by
phagocytes named as efferocytosis, are helpful de-
fense mechanisms in the host for avoiding virus
propagation. Appropriate and successful epithelial
cell apoptosis in virus-infected cells is a limiting factor
for viral replication and spreading progeny viruses to
neighboring cells to abort infection.69,70 Dying cells
should be cleared from the site of inflammation, since
viruses are able to survive and replicate in even dying
cells and dying cells are also able to release inflam-
matory mediators. Recently, it has been emphasized
that effective efferocytosis is important to clear dying
cells and to terminate the inflammation process with-
out inflammatory mediator releases.73 Thus, appropri-
ate and successful epithelial cell apoptosis, and effec-
tive effecrocytosis are critical for avoiding virus
propagation and eliminating viruses, and for terminat-
ing inflammation at the sites of the inflammation.
Clinical data on the persistence of rhinovirus mRNA
in nasal wash, after asthma exacerbation in children,
is correlated with disease severity; this could support
the biological significance of epithelial apoptosis and
efferocytosis.74
Molecular mechanisms involved in apoptosis have
been extensively investigated. A variety of stressful
factors, including respiratory virus infections, could
induce oxidative stress in the bronchial epithelial
cells. Influenza virus infection activates apoptosis-
regulating kinase-1 (ASK-1), which is a mitogen-
activated protein kinase (MAPK); this kinase is acti-
vated by oxidative stress. Influenza virus infection-
induced cell apoptosis is induced through caspase-3
activation and N-acetyl-cysteine (NAC) attenuation.75
Although epithelial cell apoptosis and efferocytosis
for aborting virus infections is an important host de-
fense mechanism against respiratory virus infections,
epithelial cell injury often results in a loss of the epi-
thelial cell barrier function; therefore, the process of
repairing epithelial cells is a crucial step for trigger-
ing the recovery of an injured airway.
CELL INJURY, APOPTOSIS AND THE REPAIR
PROCESS
Asthmatic bronchial epithelial cells are more suscep-
tible to oxidant-induced injuries and also to an
oxidant-induced increase in permeability.11,45 In vitro
studies have shown that asthmatic bronchial epithe-
lial cells have an increased number of apoptotic cells
compared to healthy control subjects. Respiratory vi-
rus infections are able to induce oxidative stress;
therefore, it might be possible that repeated viral in-
fections and an impaired repair process combined
could participate in the increased number of apop-
totic cells in asthmatics.
Cell growthproliferation is regulated by cell-
growthproliferation signals and cell cycle inhibition
signals. The bronchial epithelial cells from adult asth-
matics have shown high expression levels of epider-
mal growth factor receptor (EGFR) and cyclincyclin-
dependent kinase (CDK) inhibitor p21waf, and low ex-
pression levels of cell proliferation marker Ki67 in as-
sociation with concurrent epithelial stress and in-
jury.11 In childhood asthma, the bronchial epithelial
cells from mild or moderate asthmatics, aged 5―15
years, have shown similar findings with their bron-
chial epithelial cells as the characteristics of adults.76
This dysregulation of the expression of cell-growth
proliferation signals and cell cycle inhibition signals
could be associated with an impaired repair process.
Although epithelial cell apoptosis in virus-infected
cells is a self-limiting factor for viral replication and
the spreading of progeny virus infected cells to neigh-
boring cells, repeated cell apoptosis might result in
the production and progression of airway remodel-
ing. After bronchial epithelial cell injury, a wound-
repair process, to cover the wounded surface, occurs.
During this wound-repair process, proliferating bron-
chial epithelial cells express and produce pro-
fibrogenic cytokine transforming growth factor-β
(TGF-β).8,11,45 TGF-β has been shown to enhance
RSV replication in bronchial epithelial cells.77 Thus,
Hashimoto S et al.
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repeated infection could accelerate the airway remod-
eling process.
EPITHELIAL TIGHT JUNCTION
Tight junctions located in the apicolateral cell mem-
branes of epithelia form a barrier between adjacent
cells. The epithelial barrier function mediated by a
tight junction is regulated by the tight junction pro-
teins including claudin-1, claudin-4, occuludin, ZO-1
and junctional adhesion molecule-A.11,45,78 Functions
of these peripheral cell proteins are regulated by a
complex mechanism, but proinflammatory cytokines,
oxidants and thrombin down-regulate the functions of
bronchial epithelial junction proteins.79,80 The bron-
chial epithelial cells of asthmatics are more suscepti-
ble to oxidant-induced injury and to ozone- or nitro-
gen dioxide-induced increased permeability.11,45 Rhi-
novirus infections impair the bronchial epithelial bar-
rier function possibly through virus infection-induced
oxidative stress,81 although it has not been shown
that respiratory virus infections per se could alter the
bronchial epithelial barrier function. Thus, respira-
tory virus infections which result in increased epithe-
lial permeability allow allergens and other environ-
mental agents to invade and reach the internal milieu.
Pharmacological modulation of the epithelial barrier
function by increasing the expression and the func-
tion of junctional proteins is quite an important strat-
egy for the host defense mechanism. Azithromycin, a
macrolide antibiotic, inhibits the expression of ICAM-
1, a receptor for the rhinovirus, and it has been
shown to reduce the acute exacerbation of asthma.
Transepithelial electrical resistance (TER) is an index
of epithelial permeability. Increases in TER imply de-
creases in epithelial permeability. Azithromycin in-
creases the TER of bronchial epithelial cells by
changing the processing of tight junction proteins.82
Azithromycin-mediated processing of tight junctional
proteins may have a beneficial effect in preventing
the acute exacerbation of asthma, since cell integrity
is important for the host defense against microbes, in-
cluding virus infections, by preventing the entry of
microbes.
Filament aggregating protein (filaggrin), which is
produced in the basal epidermal layer of the skin dur-
ing the terminal differentiation of keratinocytes, ag-
gregates at the epidermal cytoskelton to form a
dense-lipid matrix that is cross-linked by transglu-
taminases to form a cornified cell envelope. This
structure, which forms the skin barrier, regulates
permeability of the skin and prevents epidermal
water loss and it also prevents the entry of allergens,
infectious organisms and toxic materials into the
host. In atopic dermatitis, the loss of the skin barrier
function, because of inherited reduction or loss of
filaggrin expression, has been shown to predispose
the host to the development of this disease.83 In bron-
chial asthma, immunohistochemical staining of bron-
chial mucosa from bronchial asthmatics and normal
healthy subjects, obtained via biopsy, has demon-
strated that filaggrin immunoreactivity is not detect-
able in biopsy specimens.84 This data does not sup-
port the hypothesis that loss or deficiency of filaggrin
expression in the bronchial mucosa is associated with
bronchial asthma. On the other hand though, Palmer
C et al. have shown that filaggrin mutations are asso-
ciated with increased asthma severity.85 Little is
known about the regulation of fillagrin expression.
Th2-type cytokines, IL-4 and IL-13 down-regulate
filaggrin expression in skin keratinocytes, but IFN-γ
is up-regulated.86 Since it is not conclusively proven
whether fillagrin is expressed in bronchial epithelial
cells or not, the effect of respiratory virus infections
on fillagrin expression is not able to be determined.
VIRUS INFECTIONS AND AIRWAY REMODEL-
ING
Respiratory virus infections may predispose to airway
remodeling of bronchial asthma. Rhinovirus infection
induces the production of vascular endothelial
growth factor (VEGF), fibroblast growth factor-2
(FGF-2) and transforming growth factor-β by bron-
chial epithelial cells, which function in both the angio-
genesis and the fibrosis processes.87 Rhinovirus in-
fection induces cell cytotoxicity and thereby reduces
the cell proliferation rate resulting in an impaired re-
pair process of the bronchial epithelial cells.88 Thusly,
rhinovirus infection in bronchial epithelial cells may
contribute to the development of airway remodeling.
Severe and repeated respiratory virus infections, in-
cluding RSV infection during infancy, is associated
with the development of subsequent bronchial
asthma later in life. In animal models of asthma, RSV
infection in allergen-exposed mice develop profound
airway inflammation and remodeling compared to
only allergen-exposed mice.89
SIGNAL TRANSDUCITON
Respiratory virus infection and dsRNA induce the
production of various cytokines, chemokines and me-
diators by bronchial epithelial cells. Much effort has
been expended to try to clarify the role of intracellu-
lar signaling molecules in eliciting cellular responses
upon virus infection. The mammalian mitogen-
activated protein kinase (MAPK) superfamily has
been molecularly characterized as follows: extracellu-
lar signal-regulated kinase (Erk); p38 MAP kinase;
and, c-Jun-NH2-terminal kinase (JNK). p38 MAP
kinase and JNK were originally identified as playing a
role in apoptosis and cytokine expression, whereas
Erk plays a central role in cell proliferation and differ-
entiation. Recent studies have suggested that each of
these kinases has some element of overlapping bio-
logical activity.90 The influenza virus infection in-
duces p38 MAP kinase and JNK to produce RANTES
in the bronchial epithelial cells,91 and rhinovirus in-
Viral Infection in Asthma
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Fig. 1 Respiratory virus infection influences asthma pathogenesis. The interaction be
tween environmental factors and intrinsic factors plays an important role in the patho
genesis of bronchial asthma. Respiratory virus infection is associated with the 
etiopathogenesis and the acute exacerbation of bronchial asthma. Bronchial epithelial 
cels are at the site of respiratory virus infection and replication. Respiratory virus infec
tion induces the production a variety of cytokines, and causes the injury epithelial cel 
and the disruption of tight junction. As consequence, airway inflammation and airway re
modeling process could occur.
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fection induces p38 MAP kinase to produce cytokines
including IL-1, IL-6, IL-8 and GM-CSF.92 ICAM-1 liga-
tion due to rhinovirus infection activates phosphatidy-
linositol 3-kinase (PI3-K) to regulate viral endocytosis
and produce cytokines and chemokines including IL-
8.43,93,94 Syk is diffusely distributed in the cytosol.
Ligation of ICAM-1 due to rhinovirus recruits Syk
into the plasma membrane and enhances the Syk-
ICAM-1 association, resulting in Syk phosphoryla-
tion. Syk phosphorylation leads to the activation of p
38 MAP kinase and IL-8 expression in bronchial epi-
thelial cells.95 Syk is well known to be an important
regulator in the Mast cell functions and Syk inhibitor
is clinically effective for the treatment of allergic
rhinitis.96 It is therefore logical to expect that Syk in-
hibitors could work to regulate rhinovirus-induced
airway inflammation and asthma-related symptoms.
THERAPEUTIC STRATEGIES
Antiviral agents against rhinovirus and other respira-
tory viruses have been developed and are quite im-
portant to effectively cure infection-related respira-
tory symptoms in infants and to prevent the develop-
ment of bronchial asthma later in life. Three main
regimens are used in the management of bronchial
asthma: inhaled corticosteroids (ICS); a combination
of ICS and long-acting β2 agonists (LABA); and, cys-
teinyl leukotriene (CysLT1) receptor antagonist
(LTRA). ICS is effective at reducing asthma-related
symptoms and the frequency of acute exacerbation;
however, ICS, and even systemic GC, are not suffi-
cient to reduce acute wheezing. The combination of
ICS and long-acting β2 agonists (LABA) synergisti-
cally suppress VEGF, EGF-2 and various other
chemokines produced by bronchial epithelial cells;97
furthermore, the combination of ICS and LABA, as a
maintenance and reliever therapy, is reported to have
an advantage as it reduces the frequency and severity
of acute exacerbation in children with asthma.98 Al-
though the role of respiratory virus infection during
childhood in the development of asthma and airway
remodeling in later life needs to be clarified, children
with asthma having repeated wheezing episodes
caused by respiratory virus infection should be
treated with a combination of ICS and LABA.
LT and CysLTs are released into the site of inflam-
mation during respiratory virus infection and cause
airway inflammation and bronchoconstriction.99,100
LTRA reduced the clinical symptoms subsequent to
RSV infection in patients 3 to 36 months of age hospi-
talized with RSV bronchiolitis.101 LTRA reduced
asthma exacerbations in 2- to 5-year old children with
intermittent asthma over 12 months of treatment.102
Short-course treatment with LTRA, for at least 7days,
introduced at the first sign of an asthma episode, re-
sulted in a modest reduction in asthma-related symp-
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toms and parental work absence in 2- to 14 year old
children with intermittent asthma.103 LTRA is thusly
useful for the treatment of viral infection-induced
asthma-related symptoms. Early intervention of ICS
combined with LTRA could prevent the development
of asthma, although the effect of LTRA on airway in-
flammation, and on the structural changes induced
by viral infection, has yet to be determined. In addi-
tion to pharmacological treatments, an anti-infla-
mmatory therapy targeting intracellular signaling
molecules and transcription factors has been investi-
gated:104,105 it is expected to be approved for use as
an inhibitor for the proinflammatory transcription fac-
tor, nuclear factor kappa B, to control airway inflam-
mation caused by a respiratory virus infection.
Genetic and environmental factor interaction is
critical for the pathogenesis of bronchial asthma. In-
fection by a respiratory virus, including rhinovirus
and respiratory syncytial virus, is common in young
children; however, determining who will develop
bronchial asthma later in life is not possible to predict
yet. Several gene variations, such as IL-4 and IL-4α
receptor and chemokine receptor CCR5, have been
shown to be associated with the susceptibility and se-
verity of respiratory virus infection.106,107 It has yet to
be clarified whether children who have these variants
will develop bronchial asthma or not; it seems though
that these children would be good candidates for
treatment with anti-RSV antibody.108
SUMMARY
Recurrent and severe respiratory virus infection in in-
fancy is a risk factor for, and may predispose to, the
development of asthma later in life. Recurrent and se-
vere respiratory virus infections may result in epithe-
lial cell injury. Injured and stressed epithelial cells
trigger the process of airway remodeling through ac-
tivation of an epithelial-mesenchymal tropic unit (Fig.
1). Histopathological studies have revealed that bron-
chial epithelial cell damage and the remodeling proc-
ess occur early in the course of childhood asthma.109
Respiratory virus infection might be a major cause of
airway inflammation and remodeling which could oc-
cur early in childhood, although further study should
be conducted to clarify the precise mechanism of
how respiratory virus infections contribute to the pro-
duction of airway inflammation and remodeling early
in childhood.
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